Thia Ventures

Thia Ventures operates as a specialized investment firm, deploying capital into early-stage companies at the nexus of food, biotechnology, and health. The firm targets biotechnological innovations, seeking ventures with defensible science, technical breakthroughs, and robust intellectual property to solve industry challenges. Its strategy emphasizes scalable global solutions.

The firm is led by Managing Partner Bart Van Hooland, Chairman Serge Schoen, and Partners Abel Rossignol and Adrien Tardy, with Samuelle Thevenet as Chief Operating Officer. They founded Thia Ventures, recognizing global shifts and sustainability demands necessitate transforming food systems. This team brings substantial experience and networks across food, biotech, and health.

Thia Ventures targets mission-driven teams developing biotechnological solutions for human and planetary health. The firm’s vision is to catalyze food system transformation by backing pioneering companies worldwide, from seed to Series A. It aims to foster impactful solutions for pressing global health and environmental issues.

High-Level Overview

Thia Ventures is an early-stage venture capital firm specializing in investments at the intersection of food, biotech, and health. Their mission centers on unlocking the economic viability of sustainable biomade products by significantly reducing the high costs of biomanufacturing, aiming to displace unsustainable petrochemical or animal-derived alternatives. They focus on sectors including biotechnology, nutrition, health, and synthetic biology, targeting innovations that can transform these industries. Thia Ventures supports startups that develop sustainable, biomade products with the potential to impact a market estimated to reach $4 trillion by 2040, thereby playing a critical role in advancing the startup ecosystem in sustainable biotech and health innovation[3][4].

Origin Story

Founded and managed by Eightstone Pte Ltd, a Capital Markets Services licensed fund management company based in Singapore, Thia Ventures operates with a team of experienced partners including Managing Partner Bart Van Hooland and Chairman Serge Schoen. The firm leverages broad industrial networks and longstanding expertise in food, biotech, and health to back early-stage ventures. While headquartered in Geneva, Switzerland, Thia Ventures has a global investment footprint, with a focus that has evolved to emphasize sustainable biomanufacturing and synthetic biology as key drivers of future growth[2][3][4].

Core Differentiators

• Unique Investment Model: Focused on early-stage ventures at the nexus of food, biotech, and health, with a strong emphasis on sustainable biomade products.
• Network Strength: Robust industrial connections across biotech, food, and health sectors, enabling strategic support beyond capital.
• Track Record: 22 investments to date, including notable startups like uFraction8, with active participation in rounds averaging six per year.
• Operating Support: Provides deep sector expertise and operational guidance, leveraging partners’ backgrounds to help startups scale effectively.
• Global Reach: Investments span multiple countries including the United States, France, China, Denmark, and Singapore, reflecting a broad geographic scope[2][4][5].

Role in the Broader Tech Landscape

Thia Ventures rides the growing global trend toward sustainable biotechnology and synthetic biology, addressing the urgent market need for alternatives to petrochemical and animal-derived products. The timing is critical as the biomade product market is projected to grow substantially by 2040, driven by increasing environmental concerns and consumer demand for sustainable solutions. By focusing on reducing biomanufacturing costs, Thia Ventures is positioned to influence the broader ecosystem by enabling startups to bring economically viable, sustainable products to market, thus accelerating the transition to a bio-based economy[3][4].

Quick Take & Future Outlook

Looking ahead, Thia Ventures is likely to deepen its investments in synthetic biology and sustainable biotech startups, capitalizing on technological advances and growing market demand. Trends such as climate-conscious consumerism, regulatory support for sustainable products, and innovations in biomanufacturing will shape their journey. Their influence is expected to expand as they help scale startups that can disrupt traditional industries with biomade alternatives, reinforcing their role as a key enabler in the sustainable biotech investment landscape[4]. This forward momentum ties back to their core mission of driving down costs and unlocking the economic potential of sustainable biomade products.